Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two ...
Results of a retrospective real-world study suggested no greater risk for major CV adverse events in patients treated with ...